Andreas Pahl

Company: Heidelberg Pharma

Job title: Chief Executive Officer

Seminars:

Targeted Cancer Therapy for Patients With 17p Deletion 3:30 pm

• Breaking down clinical profile and new phase II escalation data of HDP-101 targeting BCMA in myeloma patients • Laying out retrospective analysis and investigation in deletion models of 17p deletion as a biomarker and patient selection tool for amanitin payload ADCs • Discussing future directions for clinical development and potential for patient selection investigation…Read more

day: Conference Day Two pt 2